US Patent Issued to KATMAI PHARMACEUTICALS on Feb. 10 for "Polymorphic forms of (s)-n-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4dioxino[2,3-gquinazolin-4-amine as EGFR inhibitors" (Swiss, American, German Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,545,686, issued on Feb. 10, was assigned to KATMAI PHARMACEUTICALS INC. (Corona Del Mar, Calif.).

"Polymorphic forms of (s)-n-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4dioxino[2,3-gquinazolin-4-amine as EGFR inhibitors" was invented by Jean-Michel Vernier (San Diego), Fritz Blatter (Reinach, Switzerland), Axel Rainer Maier (Baden-Wurttemberg, Germany) and Nicolino Tufilli (Moehlin, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to polymorph forms of (S)-N-(3-bromo-2-fluorophenyl)-7-((4-methylpiperazin-1-yl)methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolin-4-amine (compound (I))...